Key points from article :
Vita Therapeutics, a cell engineering company to develop novel cellular therapies to treat muscular dystrophies and cancers.
Announced the completion of a $31 million Series B financing.
To advance lead pre-clinical program VTA-100, the newest program VTA-120, and further expand Vita’s discovery pipeline.
Since inception, Vita has raised a total of $66 million.
Vita Therapeutics’ current pipeline includes:
VTA-100 is undergoing IND studies and it combines gene correction and induced iPSC technology to treat patients with LGMD2A.
VTA-120 combines gene correction and iPSC technology to treat FSHD.
VTA-300 is an immunotherapy under development that combines CAR technology and gene editing to target multiple cancers.
“The support further validates Vita’s cell therapy platform and bring transformative therapies that target the root cause of patients with muscle disorders and cancers,” said Douglas Falk, Chief Executive Officer at Vita Therapeutics.
“The team aims to solve for treatments that go beyond symptom management to truly impact these diseases in a positive way,” said Cambrian BioPharma Chief Executive Officer, James Peyer.
